Clinical Trials Browser

INDUSTRY × lorlatinib × Clear all

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

73 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4 Completed

71 enrolled 26 charts

Carcinoma

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Advanced Non-Small Cell Lung Cancer

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT04753658 2024-09-23

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

15 enrolled 22 charts

Neuroblastoma

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Carcinoma, Non-Small-Cell Lung

NCT03726333 2024-06-21

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1 Terminated

1 enrolled 3 charts

Lung Neoplasms, Neoplasms

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT03178071 2019-11-04

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

No longer available

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive